Skip to contentB
BioCorRx Inc.
B
BICXBioCorRx Inc. Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$18.94K$18.94Kderived−77.2% vs Q4 2022 Net Income-$969.01K-$969.01KderivedN/M vs Q4 2022 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioCorRx Inc. · CIK 1443863 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$822,712N/M Operating Cash Flowderived-$533,836N/M Margins · derivedOperating margin-4344.2%−2913.5 pt vs Q4 2022
Net margin-5116.7%−3713.5 pt vs Q4 2022
ended Dec 31, 2023 · filed Apr 1, 2024 · 92 d after period end